MJNA Medical Marijuana Inc

Medical Marijuana, Inc. Announces Second Quarter Filing Date and Schedules Investor Conference Call for August 15, 2019

Medical Marijuana, Inc. Announces Second Quarter Filing Date and Schedules Investor Conference Call for August 15, 2019

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that the Company will file its second quarter financial and operational results on August 14 and will host an investor conference call at 4:30 PM ET on Thursday, Aug. 15, to discuss earnings for the quarter ending June 30, 2019.

Medical Marijuana, Inc. CEO Dr. Stuart Titus and COO Blake Schroeder will provide updates on the financial and operational performance of the Company in the second quarter of 2019, share recent research and development progress, and discuss where the company is headed for the remainder of the year and in the future.

“We are excited to share our second quarter success and help shareholders understand the initiatives the Company is currently pursuing,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are optimistic that our transparency will provide confidence and clarity on where the future of Medical Marijuana, Inc. is headed.”

Interested parties have the opportunity to submit questions concerning the Company prior to the call to Stuart Smith at SmallCapVoice.com, Inc. via email: by 12:00 PM ET on Wednesday, Aug. 14.  Prior to the call, Mr. Smith will provide the Company with a list of submitted questions based on the relevance to the shareholder base and the question’s appropriateness concerning public disclosure rules.

To access the call:

Dial-In Number: 1-857-232-0157

Access Code: 422095

For those unable to attend the conference call, a replay will be available at shortly after the call has concluded.

About Medical Marijuana, Inc.

.  Medical Marijuana, Inc. () is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including and . Medical Marijuana, Inc. was named a top CBD producer by . Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at or by visiting .

To see Medical Marijuana, Inc.'s corporate video, .

Shareholders and consumers are also encouraged to

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

CONTACT:

Public Relations Contact:

Andrew Hard

Chief Executive Officer CMW Media

P. 858-264-6600



EN
12/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medical Marijuana Inc

 PRESS RELEASE

Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on ...

Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion World’s First-Ever Publicly Traded Cannabis Company Appoints Longtime Board Member as New CEO SAN DIEGO, CA , March 14, 2023 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), a holding company with operating assets dedicated to the cannabis and hemp industries, along with portfolio investments in companies in the biotechnology industry, announced today the appointment of Dr. Timothy R. Scott as its new Chief Executive Officer, President, and Chairman of the Board. Dr. Scott takes ...

 PRESS RELEASE

Medical Marijuana, Inc. Participates in Preclinical Research Study on ...

Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries Study Carried Out by Center for Research and Advanced Studies of the IPN and the Siglo XXI National Medical Center Show Advantages of Oral Administration of CBD to Reduce Levels of Neuronal Death in Animal Model SAN DIEGO, CA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- via –  (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply c...

 PRESS RELEASE

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Two New F...

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Two New Full Spectrum Concentrations in Brazil With Competitive Price Point New Products Offer 3,000mg to 6,000mg, Will Come in Jars of 30 and 60mL, Presenting Significant Cost Savings to Rapidly Growing Brazil Market SAN DIEGO, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary launched two new fu...

 PRESS RELEASE

Medical Marijuana, Inc. Subsidiary Kannaway Expands Leadership Team Wi...

Medical Marijuana, Inc. Subsidiary Kannaway Expands Leadership Team With Appointment of Industry Veterans to Roles of Executive Vice President and Vice President of Information Technology Direct Selling Subsidiary Taps Network Marketing Legends to Lead Communication and Information Technologies as Company Continues International Expansion SAN DIEGO, CA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply ch...

 PRESS RELEASE

Medical Marijuana, Inc. Reports $4.9 Million in Net Revenue in 2022 Th...

Medical Marijuana, Inc. Reports $4.9 Million in Net Revenue in 2022 Third Quarter Financial and Operational Results SAN DIEGO, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via – (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending September 30, 2022, and provided an overview of recent operational highlights. First Quarter 2022 Financial and Operational Highlights Generated $4.9 million...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch